112 related articles for article (PubMed ID: 17511772)
1. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
[TBL] [Abstract][Full Text] [Related]
3. [Neoadjuvant hormonal therapy for prostate cancer].
Miyakita H
Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
[TBL] [Abstract][Full Text] [Related]
4. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
5. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
Miyake H; Yamanaka K; Muramaki M; Kurahashi T; Gleave M; Hara I
Oncol Rep; 2005 Nov; 14(5):1371-5. PubMed ID: 16211311
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
[TBL] [Abstract][Full Text] [Related]
8. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
11. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.
Namiki S; Saito S; Tochigi T; Kuwahara M; Ioritani N; Yoshimura K; Terai A; Koinuma N; Arai Y
Int J Urol; 2005 Feb; 12(2):173-81. PubMed ID: 15733112
[TBL] [Abstract][Full Text] [Related]
12. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Kinahan J; Sullivan LD
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):39-45; discussion 46-7. PubMed ID: 8725890
[TBL] [Abstract][Full Text] [Related]
13. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
Civantos F
Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
Garzotto M; Wajsman Z
J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
[TBL] [Abstract][Full Text] [Related]
16. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
[TBL] [Abstract][Full Text] [Related]
17. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
[TBL] [Abstract][Full Text] [Related]
18. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
19. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
Debruyne FM; Witjes WP
Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
